Physician profile
Andrew Adams
NPI 1013204742
$3,889.73
in general payments reported to CMS, 2019-2025
34 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $293 · 2024: $1,525 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,889.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.99 | 2023-2025 | Vraylar, Ubrelvy, Linzess |
| Amgen INC. | $438.24 | 2024-2025 | Repatha, Krystexxa, Otezla |
| Lilly USA, LLC | $264.09 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Ucb, INC. | $230.48 | 2023-2025 | Cimzia, Bimzelx, Briviact |
| Novo Nordisk INC | $194.05 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Ani Pharmaceuticals, INC. | $190.41 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $184.50 | 2023-2025 | Acthar |
| Cleerly, INC. | $181.39 | 2025 | Cleerly Labs |
| Axsome Therapeutics, INC. | $161.13 | 2025 | Auvelity |
| Janssen Biotech, INC. | $113.06 | 2024-2025 | Tremfya, Simponi Aria |
| Antares Pharma, INC. | $112.54 | 2025 | Xyosted |
| Glaxosmithkline, LLC. | $103.09 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $88.89 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $87.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.43 | 2024-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $75.11 | 2024-2025 | Jatenzo |
| Almatica Pharma LLC | $68.93 | 2024 | Loreev Xr, Teriparatide |
| Exact Sciences Corporation | $65.08 | 2024-2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $46.44 | 2024 | Strensiq |
| Supernus Pharmaceuticals, INC. | $44.57 | 2024 | Qelbree |
| Astellas Pharma US INC | $43.15 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $41.22 | 2025 | Gemtesa |
| Lundbeck LLC | $37.14 | 2025 | Rexulti |
| Nevro Corp. | $36.41 | 2023 | Senza |
| Bioventus LLC | $29.34 | 2025 | Xcell |
| Eisai INC. | $23.93 | 2024 | |
| Boston Scientific Corporation | $22.10 | 2024 | |
| Ibsa Pharma INC. | $22.05 | 2023 | Tirosint, Licart |
| Aurinia Pharma U.S., INC. | $19.31 | 2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $18.50 | 2025 | Hyqvia |
| Ironwood Pharmaceuticals, INC | $17.77 | 2023 | Linzess |
| Philips North America LLC | $17.72 | 2024 | (Ck7) Extended Holter |
| Esperion Therapeutics, INC. | $17.36 | 2025 | Nexletol |
| Intra-Sana Laboratories | $17.11 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.